NextCure drug gets FDA Fast Track designation

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NextCure's SIM0505 for treating ovarian cancer. This designation applies to patients with platinum-resistant ovarian cancer, potentially accelerating the drug's development and review process. Fast Track status is intended to expedite the availability of promising new medicines for serious conditions. This milestone represents significant progress for NextCure's oncology pipeline and its efforts to address unmet medical needs.